Findings from the BYLieve Cohort C updated analysis support the clinical benefit of alpelisib plus fulvestrant in patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer who were treated primarily in the third-line setting. This evidence concerns the gene ERBB2 and breast carcinoma.